Menu Back to Regulatory-Science-Forum

Overview


DIA’s mission – to work across the healthcare continuum to ensure patients receive the therapies they need – is more essential than ever during times like these. DIA acknowledges the time and effort that has gone into planning and preparing for the Forum, and trusts that everyone will understand the need to respond to current, evolving health concerns in a responsible manner. These precautions are being taken to ensure the health and safety of our entire, global DIA family.

DIA is committed to exploring all possible avenues to provide a productive setting and a fulfilling meeting experience. We appreciate your patience as we work through technical requirements and any potential challenges.


The Regulatory Science Forum is a platform for sharing knowledge derived from regulatory science research and analyses conducted at the academic, industry and regulatory levels, promoting open dialogue between all stakeholders. The Forum will discuss where more research is needed, as well as the best ways to promote the widespread implementation of findings, recommendations, and other results.

Regulatory Science informs and investigated issues and challenges related to regulatory approvals, assessment and evaluation. It can help your company to better understand the issues you are facing and find more effective solutions to getting your medicines to patients faster.

Featured topics

• Why is Regulatory Science research important?
• Regulatory Science Training and Network in European Academia
• Maximizing the Value and Impact of Regulatory Science Research
• HTA-Regulatory Cooperation
• Stakeholder & Patient Engagement
• Body of Evidence
• Complex Clinical Trials
• Pharmacovigilance
• Labelling

Who should attend?

Professionals involved in:

  • Regulatory Science
  • Regulatory Strategy
  • Regulatory Intelligence
  • Scientific Advice
  • Data analysis
  • Policy
  • Patient Engagement

Learning objectives

By attending this meeting, participants will be able to:


• Understand how Regulatory Science is used by the different stakeholders and how it informs decision making and policy;
• Discuss how to maximize this work across all stakeholders;
• Become aware of the Regulatory Science research status in Europe, how to use it in a broader spectrum and how to connect it to the bigger common goals;
• Recognize what Regulatory Science means from the Industry, Regulator & Academia perspectives;
• Discover how Regulatory Science informs and investigates matters and challenges related to regulatory approvals, assessment and evaluation;
• Interact with other stakeholders and explore practical ways to increase that.

Program Committee

  • Anthony  Humphreys, MPharm
    Anthony Humphreys, MPharm Head of the Regulatory Science and Innovation Task Force
    European Medicines Agency, Netherlands
  • Marieke  De Bruin, PharmD, PhD
    Marieke De Bruin, PharmD, PhD Director, Copenhagen Centre for Regulatory Science
    University of Copenhagen, Denmark
  • Sini  Eskola, MPharm, MSc
    Sini Eskola, MPharm, MSc Director Regulatory Affairs
    European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
  • Helga  Gardarsdottir, PhD
    Helga Gardarsdottir, PhD Associate Professor in Drug Regulatory Sciences
    Utrecht University, Netherlands
  • Inka  Heikkinen, MS, MSc
    Inka Heikkinen, MS, MSc Associate Director, Global Regulatory Policy
    Merck, Denmark
  • Anne  Morant, PhD, MSc
    Anne Morant, PhD, MSc Regulatory Science Consultant representing H. Lundbeck A/S
    Anne Morant Consulting, Denmark
  • Marjon  Pasmooij, PhD
    Marjon Pasmooij, PhD Science Programme Manager
    Medicines Evaluation Board, Netherlands
  • Sara  Torgal
    Sara Torgal Scientific Programmes Manager
    DIA, Switzerland
Load More

Contact us

Registration Questions?

Send Email
+41 61 225 51 51

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download